Comparison of Dyslipidemia Among Diabetics Versus Non Diabetics in Haemodialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-01

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* How dyslipidemia common among Diabetic and non- Diabetic Haemodialysis patients.
* How differ dyslipidemia types among Diabetic and non- Diabetic in Haemodialysis patients. (Qualitative difference).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Factors Affecting Dialysis Associated Fatigue

NCT06123806

Dialysis; Complications

NOT_YET_RECRUITING

Dialysis Adequacy in Nutritional Status in Hemodialysis Patients

NCT06108856

Dialysis Adequacy

UNKNOWN

Dyslipidemia-related Risk Factors in Dialysis

NCT02072837

Chronic Renal Disease Cardiovascular Disease Dyslipidemia

COMPLETED

Effect of Malnutrition on the Prognosis in Hemodialysis Patients

NCT00307983

Chronic Renal Failure Hemodialysis Malnutrition

UNKNOWN

Impact Of Nutritional Education Program In Hemodialysis Patients

NCT06284863

Hemodialysis Complication

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Diabetes mellitus (DM) is a metabolic disease , a consequence of defects in insulin action, secretion, or both, and there are complications associated with it, such as nephropathy, retinopathy, neuropathy, cardiovascular complications ,cerebrovascular and peripheral arterial disease. Diabetic nephropathy, which occurs in about one third of type 2 diabetic patients, is the most common factor leading to end-stage renal disease (ESRD) . A very common metabolic abnormality associated with diabetes is dyslipidemia, which is characterized by a spectrum of quantitative and qualitative changes in lipids and lipoproteinsSeveral previous studies have pursued linking blood glucose levels to serum lipid activities. The etiology of dyslipidemia appears to be centered on the increased large TAG-rich very low-density lipoprotein-cholesterol (VLDL-C) and its impaired clearance. American diabetic association (ADA) defines dyslipidemia as hypercholesterolemia ≥200 mg/dl of serum total cholesterol, hypertriglyceridemia ≥150 mg/dl of serum triglyceride, reduced high density lipoprotein cholesterol (HDL-C) \<40 mg/dl for men and \<50 mg/dl for women, elevated low density lipoprotein cholesterol (LDL-C) ≥70 mg/dl and high TC to HDL-C ratio of ≥4.5. Normal plasma lipids and lipoprotein metabolism is critical for cellular cholesterol homeostasis and protection against atherosclerosis, renal disease and other complication . A study found that people with high blood pressure and overweight or obesity have a higher risk of developing dyslipidemia ,Early detection and effective control of blood lipid levels can reduce the morbidity and mortality of CVD in patients with DM. Therefore, it is important to determine the factors associated with dyslipidemia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

diabetic dialysis patients

fifty diabetic patients on regular haemodialysis more than 6 months

haemodialysis

Intervention Type PROCEDURE

process of filtering the blood of a person whose kidneys are not working normally from uremic toxins

Non-diabetic dialysis patients

fifty Non-diabetic patients on regular haemodialysis more than 6 months

haemodialysis

Intervention Type PROCEDURE

process of filtering the blood of a person whose kidneys are not working normally from uremic toxins

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

haemodialysis

process of filtering the blood of a person whose kidneys are not working normally from uremic toxins

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged between 18 and 60 years.
* Patients undergoing regular conventional Haemodialysis for more than 6 months

Exclusion Criteria

* Peritoneal Dialysis
* Haemodiafilteration
* Acute Kidney Injury
* Nephrotic syndrome
* Hypothyroidism
* Familial hypertriglyceridemia.
* Acute pancreatitis
* Connective tissue disease.
* Decompensated liver disease
* Active malignancy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No